Table 2.
Highest level of self-reported symptoms disclosed by participants with an intact uterus at entry in the NSABP STAR/P-2 trial
| Symptoms/severity level | Tamoxifen (n = 4693)* | Raloxifene (n = 4669)* | |||
|---|---|---|---|---|---|
|
|
|
||||
| No. | % | No. | % | P | |
| Hot flashes bothersome | |||||
| No | 670 | 14.3 | 774 | 16.6 | <.0001 |
| Slightly | 692 | 14.7 | 912 | 19.5 | |
| Moderately | 1020 | 21.7 | 1031 | 22.1 | |
| Quite a bit | 1339 | 28.5 | 1215 | 26.0 | |
| Extremely | 972 | 20.7 | 737 | 15.8 | |
| Vaginal discharge bothersome | |||||
| No | 1765 | 37.6 | 2673 | 57.2 | <.0001 |
| Slightly | 1276 | 27.2 | 1194 | 25.6 | |
| Moderately | 838 | 17.9 | 484 | 10.4 | |
| Quite a bit | 551 | 11.7 | 234 | 5.0 | |
| Extremely | 263 | 5.6 | 84 | 1.8 | |
| Vaginal dryness bothersome | |||||
| No | 1432 | 30.5 | 1315 | 28.2 | <.0001 |
| Slightly | 924 | 19.7 | 893 | 19.1 | |
| Moderately | 915 | 19.5 | 822 | 17.6 | |
| Quite a bit | 802 | 17.1 | 924 | 19.8 | |
| Extremely | 620 | 13.2 | 715 | 15.3 | |
| Vaginal bleeding bothersome | |||||
| No | 3548 | 75.6 | 4042 | 86.6 | <.0001 |
| Slightly | 666 | 14.2 | 443 | 9.5 | |
| Moderately | 233 | 5.0 | 100 | 2.1 | |
| Quite a bit | 153 | 3.3 | 53 | 1.1 | |
| Extremely | 93 | 2.0 | 31 | 0.7 | |
*
Forty-six women in the tamoxifen group and 48 women in the raloxifene group opted not to complete follow-up quality-of-life questionnaires.